Our trials portfolio

ACCURE UK: The feasibility of undertaking Appendicectomy to impact upon the Clinical Course of UlceRativE Colitis - The ACCURE-UK Trial Feasibility study

Speciality: IBD

Chief Investigator: Professor Thomas Pinkney

Funded By: RfPB

Portfolio Study ID: 17515

Phase: Pilot/Feasibility

Initial Target Number of Patients: 48

ACCURE-UK 2:  An international multicentre randomised controlled trial to assess the effect of Appendectomy on the Clinical Course of UlceRativE colitis; UK Arm

Speciality: IBD

Chief Investigator: Professor Thomas Pinkney

Funded By: EME

Portfolio Study ID: 40580

Phase: Phase III

Initial Target Number of Patients: 90

AceticA: A clinical trial looking at the efficacy and optimal dose of acetic acid in burn wound infections

Speciality: Burns

Chief Investigator: Professor Naiem Moiemen

Funded By: SRMRC

Portfolio Study ID: 36451

Phase: Phase II

Initial Target Number of Patients: 20

ADaPT: Androgen precursor Dehydroepiandrosterone Pharmacokinetics in Trauma

Speciality: Trauma

Chief Investigator: Lt Col Mark Foster

Funded By: SRMRC

Portfolio Study ID: N/A

Phase: Phase II

Initial Target Number of Patients: 270

AdUP: A trial looking at a biological therapy to treat prostate cancer that has come back after radiotherapy and hormone therapy

Speciality: Prostate Cancer

Chief Investigator: Mr Prashant Patel

Funded By: MRC/Department of Health

Portfolio Study ID: 13599

Phase: Phase I

Initial Target Number of Patients: 15

BASIL-2:  Multi-centre randomised controlled trial to compare the clinical and cost-effectiveness of a ‘vein bypass first’ with a ‘best endovascular treatment first’ revascularisation strategy for severe limb ischaemia due to infra-popliteal arterial disease

Speciality: Vascular

Chief Investigator: Professor Andrew Bradbury

Funded By: HTA

Portfolio Study ID: 16699

Phase: Phase III

Initial Target Number of Patients: 600

BASIL-3: Multi-centre randomised controlled trial of clinical and cost-effectiveness of drug coated balloons, drug eluting stents and plain balloon angioplasty with bail-out bare metal stent revascularisation strategies for severe limb ischaemia due to femoro-popliteal disease.

Speciality: Vascular

Chief Investigator: Professor Andrew Bradbury

Funded By: NIHR

Portfolio Study ID: 19816

Phase: Phase III

Initial Target Number of Patients: 861

BIOMEDE: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

Speciality: Brain

Chief Investigator: Professor Darren Hargrave

Funded By: CRUK

Portfolio Study ID: N/A

Phase: Phase II

Initial Target Number of Patients: 80

CHEETAH:  Cluster randomised trial of sterile glove and instrument change at the time of wound closure to reduced surgical site infection. A trial of low and middle income countries (LMICs)

Speciality: General Surgery

Chief Investigators: Professor Dion Morton & Professor Peter Brocklehurst

Funded By: Global Surgery

Portfolio Study ID: N/A

Phase: Phase III

Initial Target Number of Patients: 600 (pilot), 12,800 (main)

compARE: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer

Speciality: Head and Neck

Chief Investigator: Professor Hisham Mehanna

Funded By: CRUK

Portfolio Study ID: 18621

Phase: Phase III

Initial Target Number of Patients: 650

CReST: The role of endoluminal stenting in the acute management of obstructing colorectal cancer

Speciality: Colorectal

Chief Investigator: Professor James Hill

Funded By: CRUK

Portfolio Study ID: 4708

Phase: Phase III

Initial Target Number of Patients: 500

CREST2: ColoRectal Stenting Trial 2 - Uncovered vs covered endoluminal stenting in the acute management of obstructing colorectal cancer in the palliative setting.

Speciality: Colorectal

Chief Investigator: Professor James Hill

Funded By: NIHR HTA

Portfolio Study ID: 32120

Phase: Phase III

Initial Target Number of Patients: 350

DESKTOP III: A randomized multicenter study to compare the efficacy of additional tumour debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer.

Speciality: Ovarian Cancer

Chief Investigator: Professor David Luesley

Funded By: CTAAC

Portfolio Study ID: 11498

Phase: Phase III

Initial Target Number of Patients: 100

EAGLE: Safe-anastomosis Programme in Colorectal Surgery

Speciality: Colorectal

Chief Investigator: Professor Dion Morton

Funded By: ESCP

Portfolio Study ID: N/A

Phase: N/A

Initial Target Number of Patients: 4400

ElaTION: The Efficacy and Cost effectiveness of Real Time Ultrasound Elastography in The Investigation Of Thyroid Nodules and the diagnosis of thyroid cancer.

Speciality: Head and Neck

Chief Investigator: Professor Hisham Mehanna

Funded By: HTA

Portfolio Study ID: 17373

Phase: Phase III

Initial Target Number of Patients: 1000

ENDCaP-C: Enhanced Neoplasia Detection and Cancer Prevention in Chronic Colitis: A Multicentre test accuracy study

Speciality: IBD

Chief Investigator: Professor Tariq Iqbal

Funded By: NIHR EME

Portfolio Study ID: 17739

Phase: Phase III

Initial Target Number of Patients: 1000

EPIVIN: A trial of Veregen cream for women with vulval intraepithelial neoplasia 

Speciality: Gynaecology Cancer

Chief Investigator: Professor David Luesley

Funded By: NIHR EME

Portfolio Study ID: 15759

Phase: Phase II

Initial Target Number of Patients: 56

FALCON: Pragmatic multicentre FActorial randomised controlled triaL testing measures to reduCe surgical site infection in lOw and middle income couNtries

Speciality: Colorectal

Chief Investigator: Professor Dion Morton

Funded By: Global Surgery

Portfolio Study ID: N/A

Phase: Phase III

Initial Target Number of Patients: 5800

FEMME: A Randomised trial of treating Fibroids with either Embolisation or Myomectomy to Measure the Effect on quality of life, among women wishing to avoid hysterectomy: the FEMME study

Speciality: Reproductive Health

Chief Investigator: Professor Klim McPherson

Funded By: NIHR HTA

Portfolio Study ID: 11877

Phase: Phase III

Initial Target Number of Patients: 224

FOxTROT: Fluoropyrimidine, Oxaliplatin and Targeted-Receptor pre-Operative Therapy for patients with high-risk, operable colon cancer

Speciality: Colorectal

Chief Investigator: Professor Dion Morton

Funded By: CRUK

Portfolio Study ID: 3771

Phase: Phase III

Initial Target Number of Patients: 1050

IIH:WT: a randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of Idiopathic Intracranial Hypertension. 

Speciality: Neurological

Chief Investigator: Professor Alexandra Sinclair

Funded By: NIHR

Portfolio Study ID: 16025

Phase: Phase III

Initial Target Number of Patients: 60

NEO-EXCEL: Neoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER-positive postmenopausal early breast cancer.

Speciality: Breast Cancer

Chief Investigator: Professor Daniel Rea

Funded By: CRUK

Portfolio Study ID: 1729

Phase: Phase III

Initial Target Number of Patients: 256

NOSTRA: Can patients with residual cancer after chemotherapy for early breast cancer be identified with multiple ultrasound-guided biopsies?

Speciality: Breast Cancer

Chief Investigator: Professor Daniel Rea

Funded By: CRUK / Roche

Portfolio Study ID: 38071

Phase: Phase III

Initial Target Number of Patients: 150

LORIS: A trial comparing surgery with active monitoring for low risk DCIS.

Speciality: Breast Cancer

Chief Investigator: Dr Matthew Wallis

Funded By: NIHR HTA

Portfolio Study ID: 16736

Phase: Phase III

Initial Target Number of Patients: 932

ROCkeTS: Refining Ovarian Cancer Test Accuracy Scores: A test accuracy study to validate new risk scores in women with symptoms of suspected ovarian cancer

Speciality: Gynaecology

Chief Investigator: Professor Sudha Sundar

Funded By: NIHR HTA

Portfolio Study ID: 17994

Phase: Diagnostic Test Accuracy Trial

Initial Target Number of Patients: 2450

ROSCO: Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neo­adjuvant 5-Fluorouracil, Epirubicin and Cyclophosphamide vs Docetaxel and Cyclophosphamide chemotherapy.

Speciality: Breast Cancer

Chief Investigator: Professor Daniel Rea

Funded By: CRUK/Celgene

Portfolio Study ID: 19069

Phase: Phase III

Initial Target Number of Patients: 1050

ROSSINI 2: Reduction Of Surgical Site Infection using several Novel Interventions

Speciality: Colorectal

Chief Investigator: Professor Thomas Pinkney

Funded By: HTA

Portfolio Study ID: 39722

Phase: Phase III

Initial Target Number of Patients: 6610

SOCQER-2: Quality of Life Study in Patients Undergoing Surgery for Ovarian Cancer

Speciality: Gynaecology Cancer

Chief Investigator: Professor Sudha Sundar

Funded By: NICE

Portfolio Study ID: 19553

Initial Target Number of Patients: 120

SMALL: Surgery versus Minimally invasive vacuum-Assisted excision for small screen-detected breast cancer – a phase III randomised multi-centre trial

Speciality: Breast Cancer

Chief Investigator: Mr Stuart McIntosh

Funded By: HTA

Portfolio Study ID: 12240119

Phase: Phase III

Initial Target Number of Patients: 801

STAR-TREC:  Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer?

Speciality: Colorectal

Chief Investigator: Professor Simon Bach

Funded By: CRUK

Portfolio Study ID: 31203

Phase: Phase III

Initial Target Number of Patients: 120

STOP-Colits Pilot Trial: A prospective, open-label, randomised pilot study to assess two possible routes of Faecal Microbiota Transplant (FMT) delivery in patients with ulcerative colitis.

Speciality: Gastroenterology

Chief Investigator: Professor Tariq Iqbal

Funded By: EME / NIHR

Portfolio Study ID: 35522

Phase: Phase III (Pilot)

Initial Target Number of Patients: 30

SUNRRISE: Single use negative pressure dressing for reduction in surgical site infection following emergency laparotomy

Speciality: IBD

Chief Investigator: Mr Richard Wilkin

Funded By: RfPB

Portfolio Study ID: 36516

Phase: Phase III

Initial Target Number of Patients: 630

TREC: Transanal Endoscopic Microsurgery (TEM) and Radiotherapy in Early Rectal Cancer

Speciality: Colorectal

Chief Investigator: Professor Simon Bach

Funded By: CRUK

Portfolio Study ID: 7589

Phase: Phase III

Initial Target Number of Patients: 46

WISTERIA: WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer

Speciality: Head and Neck

Chief Investigator: Professor Hisham Mehanna

Funded By: NAC, ECMS/AZ Alliance

Portfolio Study ID: 32918

Phase: Phase I

Initial Target Number of Patients: 42

BILCAP: A randomised clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following surgery for biliary tract cancer

Speciality: Upper GI

Chief Investigator: Professor John Primrose

Funded By: CRUK

Portfolio Study ID: 1473

Phase: Phase III

Initial Target Number of Patients: 410

FIAT:  The Fistula-In-Ano Trial comparing Surgisis® anal fistula plug versus surgeon’s preference for transsphincteric fistula-in-ano

Speciality: Colorectal

Chief Investigator: Professor David Jayne

Funded By: HTA

Portfolio Study ID: 9592

Phase: Phase III

Initial Target Number of Patients: 500

HYMN: A randomised, controlled, phase III trial comparing hyperthermia plus mitomycin (HM) to a second course of bacillus Calmette-Guérin (BCG) or standard therapy in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance BCG therapy

Speciality: Bladder Cancer

Chief Investigator: Professor John Kelly

Funded By: CRUK

Portfolio Study ID: 6553

Phase: Phase III

Initial Target Number of Patients: 242

PEGASUS: A feasibility study and open pilot two-arm randomised controlled trial comparing Pressure Garment Therapy with no Pressure Garment Therapy for the prevention of abnormal scarring after burn injury (PEGASUS)

Speciality: Plastics

Chief Investigator: Mr Naiem Moiemen

Funded By: NIHR HTA

Portfolio Study ID: 17346

Phase: Pilot/Feasibility

Initial Target Number of Patients: 88

ROCSS: Reinforcement of Closure of Stoma Site. A randomised controlled trial of reinforcement of closure of stoma site using a biological mesh

Speciality: Colorectal

Chief Investigator: Professor Aneel Bhangu

Funded By: LifeCell/RfPB

Portfolio Study ID: 13461

Phase: Phase III

Initial Target Number of Patients: 90

VITTAL: Viability Testing and Transplantation of Marginal Livers

Speciality: Liver Transplantation

Chief Investigator: Professor Darius Mirza

Funded By: Wellcome Trust

Portfolio Study ID: 32299

Phase: Phase I/II

Initial Target Number of Patients: 23